N-Acylated dopamines: A new life for the old dopamine

Dopamine: Functions, Regulation and Health Effects

Volumn , Issue , 2012, Pages 49-80

  Akimov, Mikhail G ^a   Bezuglov, Vladimir V ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892108769     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Marsden CA. Dopamine: the rewarding years. Br J Pharmacol 2006, Jan;147 Suppl 1:S136-44.
2. Siegel GJ. Basic neurochemistry : Molecular, cellular, and medical aspects. Amsterdam ; Boston : Elsevier; 2006.
3. Reis HJ, Guatimosim C, Paquet M, Santos M, Ribeiro FM, Kummer A, et al. Neuro-transmitters in the central nervous system & their implication in learning and memory processes. Curr Med Chem 2009; 16(7): 796-840.
4. Eisenhofer G, Tian H, Holmes C, Matsunaga J, Roffler-Tarlov S, Hearing VJ. Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB J 2003 Jul; 17(10): 1248-55.
5. Eisenhofer G. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol Rev 2004 Sep 1; 56(3): 331-49.
6. Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 2009 Apr; 89(2): 535-606.
7. Napolitano A, Manini P, d'Ischia M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem 2011; 18(12): 1832-45.
8. Mann SP, Hill MW. Activation and inactivation of striatal tyrosine hydroxylase: the effects of pH, ATP and cyclic AMP, S-adenosylmethionine and S-adenosyl-homocysteine. Biochem Pharmacol 1983 Nov 15; 32(22): 3369-74.
9. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67(2): 443-62.
10. Berry M. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 2004 Jul 1; 90(2): 257-71.
11. Dyck LE, Yang CR, Boulton AA. The biosynthesis of p-tyramine, m-tyramine, and beta-phenylethylamine by rat striatal slices. J Neurosci Res 1983 Jan 1; 10(2): 211-20.
12. Burchett S, Hicks T. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 2006, Aug 1;79(5-6):223-46.
13. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998 Aug 28; 249(3): 838-43.
14. Vincent SR, Hope BT. Tyrosine hydroxylase containing neurons lacking aromatic amino acid decarboxylase in the hamster brain. J Comp Neurol 1990; 295(2): 290-8.
15. Neri C, Ghelardini C, Sotak B, Palmiter RD, Guarna M, Stefano G, Bianchi E. Dopamine is necessary to endogenous morphine formation in mammalian brain in vivo. J Neurochem 2008 Sep; 106(6): 2337-44.
16. Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells: an evidence-based model. Med Sci Monit 2006, Oct;12(10):RA207-19.
17. Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999 Dec 1; 51(4): 593-628.
18. Palma PN, Bonifácio MJ, Loureiro AI, Wright LC, Learmonth DA, Soares-da-Silva P. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab Dispos 2003 Mar 1; 31(3): 250-8.
19. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995 Dec; 353(1): 116-21.
20. Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol Suppl 1999;26(53):S41-53.
21. Wang PC, Kuchel O, Buu NT, Genest J. Catecholamine glucuronidation: an important metabolic pathway for dopamine in the rat. J Neurochem 1983 May; 40(5): 1435-40.
22. Goldstein M, Musacchio JM. The formation in vivo of N-acetyldopamine and N-acetyl-3-methoxydopamine. Biochim Biophys Acta 1962 Apr 23; 58: 607-8.
23. Elchisak MA, Hausner EA. Demonstration of N-acetyldopamine in human kidney and urine. Life Sci 1984 Dec 17; 35(25): 2561-9.
24. Gaudet SJ, Slominski A, Etminan M, Pruski D, Paus R, Namboodiri MA. Identification and characterization of two isozymic forms of arylamine N-acetyltransferase in Syrian hamster skin. J Invest Dermatol 1993 Nov; 101(5): 660-5.
25. Sekeris CE, Herrlich P. Detection of N-acetyldopamine in a case of pheochromocytoma. Hoppe Seylers Z Physiol Chem 1963 Mar; 331: 289-91.
26. Westley J, Wren JJ, Mitchell HK. Phospholipides containing amino acids other than serine. I. Detection. J Biol Chem 1957 Nov; 229(1): 131-8.
27. Folch J, Lees M. Proteolipides, a new type of tissue lipoproteins; their isolation from brain. J Biol Chem 1951 Aug; 191(2): 807-17.
28. Hendler RW. Possible involvement of lipids in protein synthesis. Science 1958; 128(3316): 143-4.
29. Fukui T, Axelrod B. Amino acid incorporation into lipoidal material by cell-free liver preparations. J Am Chem Soc 1959; 81(5): 1259-60.
30. Haining JL, Fukui T, Axelrod B. Incorporation of amino acids into lipoidal material by microsomal and supernatant fractions of rat tissues. J Biol Chem 1960 Jan 1; 235: 160-4.
31. Fukui T, Axelrod B. Enzymatic formation of lipo-amino acids by rat liver preparations and the nature of the product. J Biol Chem 1961 Mar 1; 236: 811-6.
32. Colodzin M, Bachur NR, Weissbach H, Udenfriend S. Enzymatic formation of fatty acid amides of ethanolamine by rat liver microsomes. Biochem Biophys Res Commun 1963;10:165-70.
33. Bachur NR, Udenfriend S. Microsomal synthesis of fatty acid amides. J Biol Chem 1966 Mar 25; 241(6): 1308-13.
34. Devane WA, Dysarz FA3, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605-13.
35. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946-9.
36. Kolocouris N, Foscolos GB, Fytas G, Sakellariou A, Raftopoulos C, Papadopoulou-Daïfoti Z, Vamvakidès A. Dopamine amides with essential or fundamental fatty acids. Synthesis and pharmacological study. Ann Pharm Fr 1991; 49(2): 99-110.
37. Bezuglov VV, Manevich Y, Archakov AV, Bobrov MYu, Kuklev DV, Petrukhina GN, et al. Artificially functionalized polyenoic fatty acids as new lipid bioregulators. Russ J Bioorg Chem 1997; 23(3): 211-20.
38. Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, Nov 1;351 Pt 3:817-24.
39. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002 Jun 11; 99(12): 8400-5.
40. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003; 278(16): 13633-9.
41. Ostroumova TV, Markova LN, Akimov MG, Gretskaia NM, Bezuglov VV. Docosahexaenoyl dopamine in freshwater hydra: effects on regeneration and metabolic changes. Ontogenez 2010 May; 41(3): 164-7.
42. Alexander SP, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 2007 Nov; 152(5): 602-23.
43. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 2005(168):147-85.
44. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007 Apr; 114(1): 13-33.
45. Walker JM, Krey JF, Chu CJ, Huang SM. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002;121(1-2):159-72.
46. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010; 17(14): 1430-49.
47. Sancho R, de la Vega L, Macho A, Appendino G, Di Marzo V, Munoz E. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. J Immunol 2005; 175(6): 3990-9.
48. Markova LN, Ostroumova TV, Akimov MG, Bezuglov VV. N-arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra. Ontogenez 2008 Jan; 39(1): 59-63.
49. Walker JM, Krey JF, Chen JS, Vefring E, Jahnsen JA, Bradshaw H, Huang SM. Targeted lipidomics: fatty acid amides and pain modulation. Prostaglandins Other Lipid Mediat 2005, Sep;77(1-4):35-45.
50. Balvers MG, Verhoeckx KC, Witkamp RF. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, May 15;877(14-15):1583-90.
51. Losel RM, Schnetzke U, Brinkkoetter PT, Song H, Beck G, Schnuelle P, et al. N-octanoyl dopamine, a non-hemodyanic dopamine derivative, for cell protection during hypothermic organ preservation. Plos ONE 2010;5(3):e9713.
52. Shashoua VE, Hesse GW. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 1996; 58(16): 1347-57.
53. Pokorski M, Matysiak Z. Fatty acid acylation of dopamine in the carotid body. Med Hypotheses 1998 Feb; 50(2): 131-3.
54. Hu SS, Bradshaw HB, Benton VM, Chen JS, Huang SM, Minassi A, et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 2009 Jun 29; 81(4): 291-301.
55. Akimov MG, Gretskaia NM, Shevchenko KV, Shevchenko VP, Miasoedov NF, Bobrov MI, Bezuglov VV. New aspects of biosynthesis and metabolism of N-acyldopamines in rat tissues. Bioorg Khim 2007; 33(6): 648-52.
56. Akimov MG. The biosynthesis and metabolism of N-acyl dopamines in animal cells and tissues [Dissertation].[Moscow(Russia)]: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS; 2008.
57. Bezuglov VV, Gretskaya NM, Blazhenova AV, Andrianova EL, Akimov MG, Bobrov MY, et al. Arachidonoyl amino acids and arachidonoyl peptides: Synthesis and properties. Russ J Bioorg Chem 2006 May; 32(3): 231-9.
58. Vandevoorde S, Lambert DM. The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 2007 Aug 1; 4(8): 1858-81.
59. Ahmad F, Kaphalia BS, Khan MF, Ansari GAS. Fatty-acid anilides - a new conjugation pathway of aniline. Biochemical Archives 1993 May; 9(2): 111-8.
60. Khan SH, Kaphalia BS, Ansari GAS. In vitro conjugation of ethanolamine with fatty acids by rat liver subcellular fractions. J Toxicol Environ Health A 2005; 68(8): 667-76.
61. Kaphalia BS, Fritz RR, Ansari GA. Purification and characterization of rat liver microsomal fatty acid ethyl and 2-chloroethyl ester synthase and their relationship with carboxylesterase (pI 6.1). Chem Res Toxicol 1997; 10(2): 211-8.
62. Kaphalia BS, Ansari GAS. Purification and characterization of rat pancreatic fatty acid ethyl ester synthase and its structural and functional relationship to pancreatic cholesterol esterase. J Biochem Mol Toxicol 2003; 17(6): 338-45.
63. Golczak M, Imanishi Y, Kuksa V, Maeda T, Kubota R, Palczewski K. Lecithin:retinol acyltransferase is responsible for amidation of retinylamine, a potent inhibitor of the retinoid cycle. J Biol Chem 2005; 280(51): 42263-73.
64. Ruiz A, Winston A, Lim YH, Gilbert BA, Rando RR, Bok D. Molecular and biochemical characterization of lecithin retinol acyltransferase. J Biol Chem 1999; 274(6): 3834-41.
65. Liu X, Yamada N, Maruyama W, Osawa T. Formation of dopamine adducts derived from brain polyunsaturated fatty acids: Mechanism for Parkinson's disease. J Biol Chem 2008 Oct 15; 283: 34887-95.
66. Akimov MG, Nazimov IV, Gretskaya NM, Zinchenko GN, Bezuglov VV. Sulfation of N-acyl dopamines in rat tissues. Biochemistry (Mosc) 2009 Jun; 74(6): 681-5.
67. Rimmerman N, Bradshaw HB, Basnet A, Tan B, Widlanski TS, Walker JM. Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV(1) receptors. Prostaglandins Other Lipid Mediat 2009, Jan;88(1-2):10-7.
68. Tseng CF, Iwakami S, Mikajiri A, Shibuya M, Hanaoka F, Ebizuka Y, et al. Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives. Chem Pharm Bull (Tokyo) 1992 Feb; 40(2): 396-400.
69. Prusakiewicz JJ, Turman MV, Vila A, Ball HL, Al-Mestarihi AH, Di Marzo V, Marnett LJ. Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases. Archives of Biochemistry and Biophysics 2007; 464(2): 260-8.
70. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004;5(9):241.
71. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999 Aug 20; 274(34): 23679-82.
72. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276(16): 12856-63.
73. Pokorski M, Zajac D, Kapuscinski A, Matysiak Z, Czarnocki Z. Accumulation of radiolabeled N-oleoyl-dopamine in the rat carotid body. Adv Exp Med Biol 2006;580:173-8; discussion 351-9.
74. Zajac D, Matysiak Z, Czarnocki Z, Pokorski M. Membrane association of N-oleoyl-dopamine in rat brain. J Physiol Pharmacol 2006, Sep;57 Suppl 4:403-8.
75. Reilly CA, Yost GS. Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev 2006; 38(4): 685-706.
76. Kofalvi A, Pereira MF, Rebola N, Rodrigues RJ, Oliveira CR, Cunha RA. Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. Br J Pharmacol 2007 Jun; 151(4): 551-63.
77. Van Der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004; 271(10): 1827-34.
78. Connor M, Vaughan CW, Vandenberg RJ. N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol 2010 Aug; 160(8): 1857-71.
79. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 2010 Nov; 9(5): 564-73.
80. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129-80.
81. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):101-21.
82. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010 Jun; 160(3): 467-79.
83. Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D, et al. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 2001; 11(4): 447-9.
84. Peng J, Li YJ. The vanilloid receptor TRPV1: role in cardiovascular and gastrointestinal protection. Eur J Pharmacol 2010, Feb 10;627(1-3):1-7.
85. Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009 Jun; 75(6): 1262-79.
86. Vennekens R, Owsianik G, Nilius B. Vanilloid transient receptor potential cation channels: an overview. Curr Pharm Des 2008; 14(1): 18-31.
87. Premkumar LS, Qi ZH, Van Buren J, Raisinghani M. Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J Neurophysiol 2004 Mar; 91(3): 1442-9.
88. Almasi R, Szoke E, Bolcskei K, Varga A, Riedl Z, Sandor Z, et al. Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci 2008;82(11-12):644-51.
89. Medvedeva YV, Kim MS, Usachev YM. Mechanisms of prolonged presynaptic Ca2+ signaling and glutamate release induced by TRPV1 activation in rat sensory neurons. J Neurosci 2008 May 14; 28(20): 5295-311.
90. Ferreira SG, Lomaglio T, Avelino A, Cruz F, Oliveira CR, Cunha RA, Köfalvi A. N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology 2009 Mar; 56(3): 676-83.
91. Huang SM, Walker JM. Enhancement of spontaneous and heat-evoked activity in spinal nociceptive neurons by the endovanilloid/endocannabinoid N-arachidonoyldopamine (NADA). J Neurophysiol 2006; 95(2): 1207-12.
92. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003, Feb 28;463(1-3):235-72.
93. Wang Y, Wang DH. Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. J Hypertens 2007 Dec; 25(12): 2426-33.
94. Zhong B, Wang DH. N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1. Am J Physiol Heart Circ Physiol 2008, Aug;295(2):H728-35.
95. Harrison S, De Petrocellis L, Trevisani M, Benvenuti F, Bifulco M, Geppetti P, Di Marzo V. Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. Eur J Pharmacol 2003, Aug 15;475(1-3):107-14.
96. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004 Apr; 141(7): 1118-30.
97. Bolcskei K, Tekus V, Dezsi L, Szolcsanyi J, Petho G. Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat. Eur J Pain 2010 May; 14(5): 480-6.
98. Spicarova D, Palecek J. The role of the TRPV1 endogenous agonist N-Oleoyldopamine in modulation of nociceptive signaling at the spinal cord level. J Neurophysiol 2009 Jul; 102(1): 234-43.
99. Cortright DN, Krause JE, Broom DC. TRP channels and pain. Biochim Biophys Acta 2007 Aug; 1772(8): 978-88.
100. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007 May; 6(5): 357-72.
101. Ross HR, Gilmore AJ, Connor M. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 2009 Mar; 156(5): 740-50.
102. O'Sullivan SE, Kendall DA, Randall MD. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 2004 Mar; 141(5): 803-12.
103. McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 2008 Feb; 73(2): 441-50.
104. De Petrocellis L, Starowicz K, Moriello AS, Vivese M, Orlando P, Di Marzo V. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res 2007 May 15; 313(9): 1911-20.
105. Przegalinski E, Filip M, Zajac D, Pokorski M. N-oleoyl-dopamine increases locomotor activity in the rat. Int J Immunopathol Pharmacol 2006 Oct; 19(4): 897-904.
106. Konieczny J, Przegalinski E, Pokorski M. N-oleoyl-dopamine decreases muscle rigidity induced by reserpine in rats. Int J Immunopathol Pharmacol 2009 Jan; 22(1): 21-8.
107. Buznikov GA, Bezuglov VV. Polyenic acid 5-hydroxytryptamides and 3-hydroxytyramides as tools for studying of the pre-nervous biogenic monoamine functions. Ross Fiziol Zh Im I M Sechenova 2000 Sep; 86(9): 1093-108.
108. Markova LN, Ostroumova TV, Bezuglov VV, Buznikov GA. Effects of arachidonoyl dopamine, haloperidol, and their mixtures on regeneration of freshwater Hydra attenuata. Ontogenez 2004 Sep; 35(5): 298-304.
109. Goswami C, Schmidt H, Hucho F. TRPV1 at nerve endings regulates growth cone morphology and movement through cytoskeleton reorganization. FEBS J 2007 Feb; 274(3): 760-72.
110. Sancho R, Macho A, de La Vega L, Calzado MA, Fiebich BL, Appendino G, Munoz E. Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol 2004; 172(4): 2341-51.
111. Perianayagam MC, Oxenkrug GF, Jaber BL. Immune-modulating effects of melatonin, N-acetylserotonin, and N-acetyldopamine. Ann N Y Acad Sci 2005 Aug; 1053: 386-93.
112. Navarrete CM, Pérez M, de Vinuesa AG, Collado JA, Fiebich BL, Calzado MA, Muñoz E. Endogenous N-acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38 dependent pathway. Biochem Pharmacol 2010 Jun 15; 79(12): 1805-14.
113. Navarrete CM, Fiebich BL, de Vinuesa AG, Hess S, de Oliveira AC, Candelario-Jalil E, et al. Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. J Neurochem 2009 Apr; 109(2): 452-64.
114. Bjorklund E, Noren E, Nilsson J, Fowler CJ. Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br J Pharmacol 2010 Dec; 161(7): 1512-26.
115. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007 Nov; 152(5): 576-82.
116. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010 Aug; 215(8): 611-6.
117. Gaddis BD, Rubert Pérez CM, Chmielewski J. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett 2008 Apr 1; 18(7): 2467-70.
118. Bobrov MY, Lyzhin AA, Andrianova EL, Gretskaya NM, Zinchenko GN, Frumkina LE, et al. Antioxidant and neuroprotective properties of N-docosahexaenoyl dopamine. Bull Exp Biol Med 2006 Oct; 142(4): 425-7.
119. Bobrov MY, Lizhin AA, Andrianova EL, Gretskaya NM, Frumkina LE, Khaspekov LG, Bezuglov VV. Antioxidant and neuroprotective properties of N-arachidonoyldopamine. Neurosci Lett 2008 Jan 24; 431(1): 6-11.
120. Oxenkrug GF, Requintina PJ. N-acetyldopamine inhibits rat brain lipid peroxidation induced by lipopolysaccharide. Ann N Y Acad Sci 2005 Aug; 1053: 394-9.
121. Andrianova EL, Bobrov MY, Gretskaya NM, Zinchenko GN, Serkov IV, Fomina-Ageeva EV, Bezuglov VV. The effects of neurolipins and their synthetic analogues on normal and transformed glial cells. Neurochem J 2010; 4(1): 46-54.
122. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008, Apr;18(4):165-73.
123. Serkov IV, Shevtsova EF, Dubova LG, Kireeva EG, Vishnevskaya EM, Gretskaya NM, et al. Interaction of docosahexaenoic acid derivatives with mitochondria. Dokl Biol Sci 2007;414:187-9.
124. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 2007 Feb; 32(2): 298-308.
125. Sagar DR, Smith PA, Millns PJ, Smart D, Kendall DA, Chapman V. TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur J Neurosci 2004 Jul; 20(1): 175-84.
126. Bennett DJ, Kirby GW. Constitution and biosynthesis of capsaicin. Journal of the Chemical Society C: Organic 1968:442-6.
127. Prasad BC, Gururaj HB, Kumar V, Giridhar P, Ravishankar GA. Valine pathway is more crucial than phenyl propanoid pathway in regulating capsaicin biosynthesis in Capsicum frutescens mill. J Agric Food Chem 2006 Sep 6; 54(18): 6660-6.
128. Pokorski M, Matysiak Z. Fatty acid acylation of dopamine in the carotid body. Med Hypotheses 1998; 50(2): 131-3.
129. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 2010 Dec 9; 68(5): 815-34.
130. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007; 30: 259-88.
131. Chahl LA. TRP's: links to schizophrenia? Biochim Biophys Acta 2007, Aug;1772(8):968-77.
132. Verhoeckx KC, Voortman T, Balvers MG, Hendriks HF, M Wortelboer H, Witkamp RF. Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. Biochim Biophys Acta 2011 Jul 21; 1811(10): 578-86.